Current:Home > ScamsFDA authorizes first revamp of COVID vaccines to target omicron -FinTechWorld
FDA authorizes first revamp of COVID vaccines to target omicron
View
Date:2025-04-17 11:43:55
The Food and Drug Administation authorized reformulated versions of the Moderna and Pfizer-BioNTech vaccines that aim to protect against the omicron variant.
The new shots target both the original strain of the coronavirus and the omicron BA.4/BA.5 subvariants that most people are catching now. This double-barreled vaccine is called a bivalent vaccine.
"The FDA has been planning for the possibility that the composition of the COVID-19 vaccines would need to be modified to address circulating variants. ... We have worked closely with the vaccine manufacturers to ensure the development of these updated boosters was done safely and efficiently," said Dr. Peter Marks, director of the FDA's Center for Biologics Evaluation and Research, in an agency statement. "The FDA has extensive experience with strain changes for annual influenza vaccines. We are confident in the evidence supporting these authorizations."
The Moderna COVID-19 vaccine is authorized for use as a single booster dose in people 18 and older. The Pfizer-BioNTech booster is authorized for people 12 years and up. People are eligible for the new boosters two months after completing their initial vaccination or their last booster shot.
The federal government plans to make the boosters available starting next week. In advance of the FDA's decision, Dr. Ashish Jha, the White House COVID-19 Response Coordinator told NPR that the new boosters represented "a really important moment in this pandemic."
Public health officials hope they will help contain a possible fall and winter surge.
But there is also skepticism about how big a difference the boosters can make. "It could be problematic if the public thinks that the new bivalent boosters are a super-strong shield against infection, and hence increased their behavioral risk and exposed themselves to more virus," John Moore, an immunologist at Weill Cornell Medicine in New York, told NPR before the FDA decision.
veryGood! (1)
Related
- Sam Taylor
- Olympic medalist Tori Bowie died in childbirth. What to know about maternal mortality, eclampsia and other labor complications.
- Videos like the Tyre Nichols footage can be traumatic. An expert shares ways to cope
- Ohio to Build First Offshore Wind Farm in Great Lakes, Aims to Boost Local Industry
- Apple iOS 18.2: What to know about top features, including Genmoji, AI updates
- Dakota Access Protest ‘Felt Like Low-Grade War,’ Says Medic Treating Injuries
- Denver Nuggets defeat Miami Heat for franchise's first NBA title
- Sunnylife’s Long Weekend Must-Haves Make Any Day a Day at the Beach
- Apple iOS 18.2: What to know about top features, including Genmoji, AI updates
- Keith Urban Accidentally Films Phoebe Bridgers and Bo Burnham Kissing at Taylor Swift's Concert
Ranking
- See you latte: Starbucks plans to cut 30% of its menu
- 9 wounded in Denver shooting near Nuggets' Ball Arena as fans celebrated, police say
- Federal Report Urges Shoring Up Aging Natural Gas Storage Facilities to Prevent Leaks
- Debunking Climate Change Myths: A Holiday Conversation Guide
- Justice Department, Louisville reach deal after probe prompted by Breonna Taylor killing
- Ukraine: Under The Counter
- Solar Acquisition Paying Off for Powertool Giant Hilti
- Seattle's schools are suing tech giants for harming young people's mental health
Recommendation
McConnell absent from Senate on Thursday as he recovers from fall in Capitol
Therapy by chatbot? The promise and challenges in using AI for mental health
From a green comet to cancer-sniffing ants, we break down the science headlines
Harry Jowsey Reacts to Ex Francesca Farago's Engagement to Jesse Sullivan
The Super Bowl could end in a 'three
Ukraine: The Handoff
Ohio to Build First Offshore Wind Farm in Great Lakes, Aims to Boost Local Industry
Solar Acquisition Paying Off for Powertool Giant Hilti